Education
About Us
Working with TipRanks
Follow Us
Sernova (TSE:SVA)
TSX:SVA
SVA Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.15 - C$0.40
Previous CloseN/A
Volume71.45K
Average Volume (3M)111.48K
Market Cap
C$64.05M
Enterprise ValueC$63.39M
Total Cash (Recent Filing)C$1.21M
Total Debt (Recent Filing)C$546.47K
Price to Earnings (P/E)―
Beta-0.66
Next Earnings
Jun 25, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding328,484,770
10 Day Avg. Volume75,019
30 Day Avg. Volume111,477
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)-3.56
Price to Sales (P/S)0.00
P/FCF Ratio-3.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.00Price Target Upside2900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Sernova News
PremiumCompany Announcements
Sernova Biotherapeutics Secures $4 Million Loan for Clinical Advancements
PremiumCompany Announcements
Sernova Advances Clinical Trial for Diabetes Treatment with Promising Results
PremiumCompany Announcements
Sernova Biotherapeutics Secures FDA Clearance for Thyroid Cell Therapy Trial
PremiumCompany Announcements
Sernova Submits IND for Cell Pouch Hybrid Organ in Hypothyroidism Treatment---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressDeep responses in diabetes patients position the technology for potential commercial success, particularly as competitors exit the space, and the impressive response rates and durability support Sernova's strategy and justify further investigation.
Market OpportunitySubmission of an IND application for the Cell Pouch device in hypothyroidism could address a significant market opportunity estimated at approximately $2.2 billion.
Regulatory MilestonesEncouragement by the Phase 1/2's progress includes a recent green light from the trial's DSMB, with anticipation for data that should provide welcome guidance related to the design, initiation, and timeline of a possible Phase 3 pivotal study.
Bears Say
Interim Clinical DataDespite these data coming from an interim clinical evaluation, these are clear efficacy signals and the safety profile has remained favorable.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.10% Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
95.90% Public Companies and
Individual Investors
SVA FAQ
What was Sernova’s price range in the past 12 months?
Sernova lowest stock price was C$0.15 and its highest was C$0.40 in the past 12 months.
What is Sernova’s market cap?
Sernova’s market cap is C$64.05M.
When is Sernova’s upcoming earnings report date?
Sernova’s upcoming earnings report date is Jun 25, 2025 which is in 43 days.
How were Sernova’s earnings last quarter?
Sernova released its earnings results on Mar 14, 2025. The company reported -C$0.018 earnings per share for the quarter, beating the consensus estimate of -C$0.028 by C$0.01.
Is Sernova overvalued?
According to Wall Street analysts Sernova’s price is currently Undervalued.
Does Sernova pay dividends?
Sernova does not currently pay dividends.
What is Sernova’s EPS estimate?
Sernova’s EPS estimate is -0.02.
How many shares outstanding does Sernova have?
Sernova has 328,484,770 shares outstanding.
What happened to Sernova’s price movement after its last earnings report?
Sernova reported an EPS of -C$0.018 in its last earnings report, beating expectations of -C$0.028. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sernova?
Currently, no hedge funds are holding shares in TSE:SVA
---
Sernova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$6.00 (2900.00% Upside)
C$6.00 (2900.00% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.83%
12-Months-Change
Fundamentals
Return on Equity
248.46%
Trailing 12-Months
Asset Growth
-83.43%
Trailing 12-Months
Company Description
Sernova
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
---
SVA Stock 12 Month Forecast
Average Price Target
C$6.00
▲(2900.00% Upside)
Technical Analysis
Oncolytics Biotech
―
Medicenna Therapeutics Corp
―
Covalon Technologies
―
Microbix Biosystms
―
Medmira
―
---